Get started
Author

Xiaoting Fei

Observed name: X. Fei
ORCID: 0000-0003-3710-8077
Observed ORCID: 0000-0003-3710-8077
OpenAlex ID: A5011153539
HDAC-targeting epigenetic modulators for cancer immunotherapy
2024 · Binbin Cheng, Wei Pan, et al. · European Journal of Medicinal Chemistry · 119
Recent Progress in DNA Damage Response-Targeting PROTAC Degraders
2024 · Binbin Cheng, Xiaoting Fei, et al. · Journal of Medicinal Chemistry · 28
Discovery of Novel d -(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for Targeted Cancer Immunotherapy
2023 · Zongbao Ding, Shuanghu Wang, et al. · Journal of Medicinal Chemistry · 24
Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual Immunotherapy
2024 · Shuanghu Wang, Zhihua Kong, et al. · Journal of Medicinal Chemistry · 23
Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009–2024)
2024 · Binbin Cheng, Xianshi Ma, et al. · European Journal of Medicinal Chemistry · 18
Discovery of Novel Heterotricyclic Compounds as DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Enhanced Chemosensitivity, Oral Bioavailability, and the Ability to Potentiate Cancer Immunotherapy
2024 · Binbin Cheng, Yaru Shi, et al. · Journal of Medicinal Chemistry · 8
466P Integrated analysis of potential prognosis and differential expression between primary and metastatic foci for COL12A1 in breast cancer
2023 · L. Tang, H. Xu, et al. · Annals of Oncology · 1
PDF
Heterogenous Genomic Features in Viscerally-Metastatic Prostate Cancer
2021 · Y. Gong, X. Fei, et al. · European Urology
Sat-269 Single or Dual Use Renin-angiotensin System Inhibitors on Residual Renal Function in Patients Receiving Continuous Ambulatory Peritoneal Dialysis
2020 · L. FAN, H. Mao, et al. · Kidney International Reports
Works count: 9
Citation count: 221
H-index: 6
I10-index: 5
Year
Topic
Type